Validation of an Ultrashort Persian Version of Oral Health Impact Profile (OHIP-5) Questionnaire

Abstract Objective: To validate the ultrashort (5-item) Persian version of OHIP by investigating its psychometric properties. Material and Methods: Construct validity was assessed by examining the correlation between OHIP-5 scores and self-reported oral health status, judgment for dental treatment needs and the number of natural teeth. Reliability was calculated using Cronbach's alpha and corrected item-total correlation. Effect size (ES) and Standardized Response Mean (SRM) were calculated for the responsiveness of the scale and factor analysis was done by measuring Kaiser-Meyer-Olkin (KMO), Bartlett's sphericity test and scree plot. Results: In 430 subjects (mean age 41.56+/-11.35 years, 56% female) the correlations between OHIP-5 scores and mentioned items were significant (p<0.01) indicating sufficient construct validity. The reliability coefficient (Cronbach's alpha) of the OHIP-5 was above the recommended 0.7 thresholds (0.809) and considered well. For evaluation of responsiveness, the ES was measured to be 5.604 and the SRM was 1.5. Moreover, in the confirmatory factor analysis, the unidimensional model for OHIP5 approved by indices (KMO=0.81, p<0.001 for Bartlett sphericity). Conclusion: The Persian version of OHIP-5 is a precise, valid, reliable and unidimensional instrument for assessing oral health-related quality of life among the general adult population.

The efficacy of domperidone in the treatment of childhood Gatroesophageal reflux disease: report of 220 cases.

The aim of this study was to investigate the efficacy and side effects of domperidone in childhood gastroesophageal reflux disease. This outcome study was done on 220 children (1month -15years) referred with reflux-related gastrointestinal and extra gastrointestinal symptoms during 3 years. Upper endoscopy with biopsy was performed in all subjects except in infants with apnea. Trial therapy was begun with domperidone (0.6mg/kg/BID) 30 minutes before meal. The efficacy and side effects were evaluated in 4-week follow up. Those free of symptom were considered as positive therapeutic response. In children with esophagitis, omeprazol was prescribed for 3 months too. Follow up continued monthly for three months and then every 3-6 months up to 2 years. Mean age of subjects was 4.99 ±3.5 years. There was no significant different between two sex(female=55%, male=45%).There was poor correlation between clinical symptoms with endoscopic and histologic findings (100%, 66.4%, 82.7%). Majority of the patients (85.5%) responded to the treatment in 4 weeks. There was no significant relationship between age, sex and clinical symptoms with response to domperidone. Although side effects were observed in 22.4%, but the most frequent side effect (15%) was loose stool .Moreover this complication (constipation) was beneficial in relieving simultaneous reflux related constipation. Serious complications such as extrapyramidal signs were observed only in 0.5%. According to this study, domperidone with few side effects can be efficient for the treatment of reflux in children with any gastrointestinal or extra- gastrointestinal symptom regardless of the sex or age group, moreover further study for finding out rare complications is suggested too.